RE:RE:Just $1.11 above IPO price of $3.50 Google search -
In early March, and just two days after its shares were listed on the TSX-Venture Exchange, the company announced a $71-million financing via the sale of 20.3 million special warrants at $3.50 per warrant. As things materialized the financing ended up at $75-million after the underwriters exercised the over-allotment option. On that deal, Goodman’s private company invested about $21-million
One reason for the difference in price between the two deals — $3.50 in early March and $5.25 on Friday — is that the company received approval from the U.S. FDA for its Impavido drug. “In short, it has been an incredibly fun and successful first three weeks of [our] existence,” noted Goodman, in a statement on Friday.